Orion Oyj

Share Issue/Capital Change • Aug 14, 2024

Disclosure 449437

Orion - Other information disclosed according to the rules of the Exchange

44,767 Orion Corporation A shares converted into B shares

ORION CORPORATION

STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE

14 AUGUST 2024 at 9.30 EEST

44,767 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 44,767 A shares have been converted into 44,767 B shares. The conversion has been entered into the Trade Register on 14 August 2024.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 33,187,594 A shares and 107,946,684 B shares. The number of votes of the company's shares is after the conversion 771,698,564.

Orion Corporation

René Lindell CFO		Olli Huotari SVP, Corporate Functions

Contact person:

Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.